Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
暂无分享,去创建一个
H. Sather | F. Uckun | M. Sensel | M. Trigg | P. Gaynon | J. Lukens | J. Nachman | J. Cherlow | F. Uckun | L. Wolff
[1] H. Sather,et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Sather,et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.
[3] M. Schrappe,et al. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Pui,et al. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children , 1996, The Lancet.
[5] H. Sather,et al. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Pui,et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. , 1995, Blood.
[7] F. Behm,et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[9] J. Shuster,et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Harbott,et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark , 1994 .
[11] B. Camitta,et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Hancock,et al. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. , 1993, The New England journal of medicine.
[13] S. Raimondi. Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .
[14] H. Sather,et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Sather,et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Garand,et al. Incidence, clinical and laboratory features, and prognostic significance of immunophenotypic subgroups in acute lymphoblastic leukemia: the GEIL experience. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[17] C. Pui. Acute leukemias with the t(4;11)(q21;q23). , 1992, Leukemia & lymphoma.
[18] L. Frankel,et al. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. , 1992, Leukemia.
[19] Denis R. Miller,et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure , 1991, Cancer.
[20] J J Shuster,et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. , 1991, Blood.
[21] Jonathan J. Shuster,et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study , 1990 .
[22] F. Behm,et al. Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. , 1990, Leukemia.
[23] H. Sather,et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.
[24] F. Behm,et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.
[25] H. Sather,et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.
[26] J. Ritter,et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .
[27] Y. Kaneko,et al. Balanced and unbalanced 1;19 translocation‐associated acute lymphoblastic leukemias , 1986, Cancer.
[28] R. Gelber,et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.
[29] A. Bleyer,et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Pullen,et al. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.
[31] A. Bleyer,et al. Analysis of prognostic factors in acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.
[32] J. Lilleyman,et al. United Kingdom Medical Research Council Acute Lymphoblastic Leukaemia (UKALL) Trials I-VIII: clinical features and results of treatment in four groups of children with adverse prognostic features. , 1986, Medical and pediatric oncology.
[33] C. R. Pinkerton,et al. Modified Capizzi maintenance regimen in children with relapsed acute lymphoblastic leukaemia. , 1986, Medical and pediatric oncology.
[34] Walker,et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. , 1986, Blood.
[35] T R Fleming,et al. Designs for group sequential tests. , 1984, Controlled clinical trials.
[36] Denis R. Miller,et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG‐141: A report from childrens cancer study group , 1983, Cancer.
[37] K. Starling,et al. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). , 1982, Blood.
[38] H. Gadner,et al. Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen* , 1981 .
[39] G. Duvel. The study group. , 1980 .
[40] S. Sallan,et al. Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. , 1978, Blood.
[41] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[42] N. Breslow,et al. Analysis of Survival Data under the Proportional Hazards Model , 1975 .
[43] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[44] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .